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Chronic inﬂammation is a well-recognized risk factor for development of human cancer in several tissues, including large
bowel. Inﬂammatory bowel disease, including ulcerative colitis and Crohn’s disease, is a longstanding inﬂammatory disease of
intestinewith increased riskforcolorectal cancer development. Several molecular events involved inchronic inﬂammatoryprocess
may contribute to multistep carcinogenesis of human colorectal cancer in the inﬂamed colon. They include overproduction
of reactive oxygen and nitrogen species, overproduction and upregulation of productions and enzymes of arachidonic acid
biosynthesis pathway and cytokines, and intestinal immune system dysfunction. In this paper, I will describe several methods
to induce colorectal neoplasm in the inﬂamed colon. First, I will introduce a protocol of a novel inﬂammation-associated colon
carcinogenesis in mice. In addition, powerful tumor-promotion/progression activity of dextran sodium sulfate in the large bowel
of ApcMin/+ mice will be described. Finally, chemoprevention of inﬂammation-associated colon carcinogenesis will be mentioned.
1.Introduction
Relationship between inﬂammation and cancer has been
suggested for a long time [1]. Since Marshall and Warren [2],
who discovered Helicobacter pylori and reported its infection
closely associated with gastric cancer development, won the
Nobel Prize in Physiology or Medicine in 2005, there have
been an increasing number of reports on PubMed as to the
relationship between inﬂammation and carcinogenesis in a
variety of tissues (Table 1) and it has been featured in major
journals.
In terms of the large bowel, it has been found
that the risk of colorectal cancer increases in relation
to the degrees of inﬂammation and the disease dura-
tion (duration/risk = 10 years/1.6%, 20 years/8.3%, and 30
years/18.4%) in inﬂammatory bowl diseases (IBDs) such as
ulcerative colitis (UC) and Crohn’s disease (CD) (Figure 1)
[3]. I have been interested in inﬂammation-associated col-
orectal carcinogenesis for a long time, since even younger
patients with UC have high risk of colorectal cancer [4].
Patients with UC as well as those with colorectal cancer
have been increasing in Asian countries including Japan,
similarly to Western countries (Figure 2)[ 5]. Therefore,
it is necessary to investigate the mechanisms of colorectal
cancer development with the background of inﬂammation
for establishing the countermeasure strategy such as chemo-
prevention [6–8]. To this end, a novel animal model is
required but there have been few useful animal models. In
this paper, I would like to introduce details of my short-term
mouseandratcolorectalcancermodelswiththebackground
of colitis mimicking human UC and our exploration of
chemopreventive agents using these models [6–8].2 International Journal of Inﬂammation
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Figure 1: UC patients are high-risk groups of colorectal cancer (CRC) development.
Table 1: Inﬂammation and cancer in various tissues.
Chronic inﬂammation Site and associated cancer
Chewing tobacco, Oral irritation Oral squamous cell carcinoma
Smoking, Chronic bronchitis, Chronic Lung cancer
obstructive pulmonary disease
Asbestosis Mesothelioma
Reﬂux esophagitis, Barrett’s esophagus Esophageal adenocarcinoma
H. pylori-induced gastritis Gastric cancer, Mucosa-associated lymphoid tissue lymphoma
Chronic pancreatitis Pancreatic adenocarcinoma
Viral (Hepatitis B and C virus) hepatitis Hepatocellular carcinoma
Opisthorchis sinensis infection (liver ﬂuke) Cholangio carcinoma
Inﬂammatory bowel disease (IBD) Colorectal adenocarcinoma
Pelvic inﬂammatory disease Ovarian cancer
Human papilloma virus (HPV) infection Anogenital carcinoma
Schistosomiasis Bladder cancer
Chronic scar tissue Scar cancer arising in pre-existing scars in the lung, skin, and other tissues
Human herpes simplex virus type 8 Kaposi sarcoma
Chronic oesteomyelitis Osteosarcoma
2. Processof HumanColorectal Carcinogenesis
There are at least four types of human colorectal car-
cinogenesis (adenoma-carcinoma sequence type, hereditary
nonpolyposis colorectal cancer (HNPCC) type, de novo type,
and colitic cancer type) (Figure 3)[ 9]. Of them, the colitic
(colitis-associated) cancer type arises from the background
of colitis and DNA injury is induced by production of
free radicals by the inducible nitric oxide synthase (iNOS)
system in the colonic mucosa with persistent inﬂammation,
followed by p53 mutation and development of dysplasia,
a precancerous lesion. Furthermore, dysplasia is advanced
by cyclooxygenase- (COX-) 2, iNOS, and several cytokines
produced in the inﬁltrated inﬂammatory cells and accumu-
lation of genetic abnormality, such as a loss of the DCC gene,
leadstoinvasivecolorectalcancer.Unlikecommoncolorectal
cancer (adenoma-carcinoma sequence type), it has been
thought that the APC and K-ras genes and microsatellite
instability (MSI) are hardly involved in this type, but there
remains to be further discussed [9].International Journal of Inﬂammation 3
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Figure 2: Risk of colorectal cancer.
3.Development of an Inﬂammation-Associated
Colorectal Cancer Model
Rats have mostly been employed for an animal colorectal
carcinogenesis model, and azoxymethane (AOM), methyla-
zoxymethanol (MAM) acetate, and 1,2-dimethylhydrazine
(DMH) have been widely used as colorectal carcinogenic
substances (Table 2)[ 10]. About 30 weeks are required for
developmentofcolorectalcancerinabouthalfofratsthatare
initiated with the colonic carcinogens. On the other hand,
in experiments and studies using mice, multiple adminis-
trations of similar colorectal carcinogens are required and it
takes a long term of 40 weeks or longer to develop colorectal
cancer [11]. Therefore, I tried to develop a novel mouse
modelthatwoulddevelopcolorectalcancerinashorttermin
the inﬂamed colon [12]. To settle the issue of the inﬂuence of
peroxisome proliferator-activated receptor (PPAR) agonists
on colorectal carcinogenesis, which has been a topic on the
journal Nat Med since 1998 [13–15], we conﬁrmed that
colitis inducing dextran sodium sulfate (DSS), employed in
an experiment using rats with aberrant crypt foci (ACF) as a
biologicalmarker(Figure4)[9,16–18],hadtumorpromoter
activity to accelerate development of ACF and hypothesized
thatacombinationofDSSandAOMwouldinducecolorectal
cancer in a short-term period in mice as well [19].
Since DSS is a nongenotoxic carcinogen [20], male ICR
mice were divided into three groups that received diﬀerent
administration patterns: DSS→AOM, AOM during DSS
administration, and AOM→DSS (Figure 5). In the groups
of DSS→AOM and AOM →DSS, there was a one-week
interval between the treatments [12]. DSS was given at the
concentration of 2% in drinking water (distilled water) for
one week and AOM was administered intraperitoneally once
at a low dose of 10mg/kg body weight, which could not
induce colorectal tumors, namely, the low-dose initiation.
Interestingly, many colorectal tumors (tubular adenomas4 International Journal of Inﬂammation
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Figure 4: Chemical structure of dextran sulfate sodium (DSS), a sulfated polysaccharide, and its biological activities. DSS (1–5% in drinking
water or diet) induces colitis in rodents. Treatment with DSS (1% in diet) after DMH exposure produces colonic adenocarcinoma [44].
The tumorigenicityof DSS is non-genotoxic eﬀects [20]. Cycle treatment with 3% DSS (MW 54,000, 7 days) and distilled water (14 days)
produces colonic tumors [45]. DSS increases the number of ACF induced by AOM [19].
and tubular adenocarcinomas) developed in the distal colon,
where DSS could induce severe colitis, of mice in the group
of AOM→DSS. On the other hand, mice of other groups
(the DSS→AOM and the AOM during DSS administration
groups) did not develop colorectal tumors. The ﬁndings
conﬁrm potent tumor-promotion activity of DSS (Figure 6).
At the same time, the results reconﬁrmed importance of
inﬂammation in colorectal carcinogenesis [12]. In addition,
accumulation of β-catenin in the nuclei of colorectal adeno-
carcinoma cells was observed.International Journal of Inﬂammation 5
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Figure 5:Experimentalprotocoltodevelopaninﬂammation-associatedmousecoloncarcinogenesismodel,todevelopanewinﬂammation-
related mouse colon carcinogenesis model [12].
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Figure 8: Macroscopic view and histopathology of colonic tumors developed in mice that received AOM and DSS (0.5%, 1%, or 2% DSS in
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Dose dependence of tumor-promotion activity of DSS
after a single intraperitoneal administration of AOM
(10mg/kg body weight) was subsequently examined at ﬁve
doses (0.1%, 0.25%, 0.5%, 1%, and 2%) of DSS (Figure 7)
[21]. The ﬁndings indicated that tumor-promotion activity
DSS was not observed at the concentration 0.25% or lower
and only one tubular adenoma developed in a mouse
that received AOM and 0.5% DSS. Colorectal tumors were
developed in all mice by the treatment with 1% DSS and
2% DSS after AOM initiation and the number of colorectal
adenocarcinoma was much greater in the group of mice
treated with 2% DSS (Figure 8). The severity of colonic
inﬂammation was determined by the histological inﬂamma-
tion score and immunohistochemical nitrotyrosine-positive
reactivity. Both the inﬂammation score and nitrotyrosine-
positive score in inﬂammatory cells that inﬁltrated colonicInternational Journal of Inﬂammation 7
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Figure 9: Inﬂammation and nitrotyrosine-positive scores in the colon of mice that received AOM and/or DSS (0.1%, 0.25%, 0.5%, 1%, or
2% DSS in drinking water). (a) Signiﬁcantly diﬀerent: a (P<0.05), versus AOM→0.5% DSS group; b (P<0.05), versus AOM→0.1%
DSS group; c (P<0.01) and d (P<0.05), versus AOM alone group; e (P<0.05), versus 2% DSS alone group; and f (P<0.001), g
(P<0.005), h (P<0.01), and i (P<0.05), versus no treatment group. (b) Signiﬁcantly diﬀerent: a (P<0.001), versus AOM→0.5% DSS
g r o u p ;b( P<0.001) and c (P<0.05), versus AOM→0.25% DSS group; d (P<0.001) and e (P<0.01), versus AOM→0.1% DSS group; f
(P<0.001) and g (P<0.05), versus AOM alone group; h (P<0.005), versus 2% DSS alone group; and i (P<0.001) and j (P<0.05), versus
no treatment group.
mucosawerehigherinmicethatreceivedhigherdosesofDSS
after AOM, suggesting that inﬂammation and nitrosation
were involved in the tumor-promotion activity of DSS
(Figure 9).
Time-course observation during AOM/DSS-induced
mouse colorectal carcinogenesis was conducted to determine
when colonic tumors occur in the inﬂamed colon of
mice that received 2% DSS after the AOM initiation [22].
Male ICR mice were initiated with a single intraperitoneal
injection of AOM (10mg/kg body weight) and followed
by one week administration with 2% DSS in drinking
water. Our time-course observation revealed that colorectal
adenoma and adenocarcinoma developed three and four
weeks after AOM administration, respectively, and the
numbers increased in a time-dependent manner during the
follow-up period up to 14 weeks (Figure 10). Interesting
ﬁnding of this study was that the high inﬂammation score
and high nitrotyrosine-positive score lasted until ﬁve to six
weeks after the cessation of DSS administration (Figure 11).
Since mucosal ulcer caused by DSS administration was
microscopically repaired at this point, persistence of the high
nitrotyrosine-positive score, rather than the high inﬂamma-
toryscore,isintriguingaswellasstrongiNOSexpressionand
weak PPARγ expression in the colonic mucosa at ﬁve and 10
weeks after the AOM administration (Figure 12).
Instead of AOM, experiments with DMH [23] or a het-
erocyclic amine, 2-amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine (PhIP) [24] as an initiator (colonic carcinogene)
and followed by DSS treatment showed similar results
described previously (Figure 13). Histopathologically, ade-
nocarcinoma induced by DMH/DSS showed severer atypia
and more aggressive biological natures than that induced by
AOM/DSS. As noticed in the cancers induced by AOM/DSS,
the adenocarcinoma cells developed in the inﬂamed colon of
mice that received DMH and DSS were positive for COX-
2, iNOS, and β-catenin (Figure 14). Mutation patterns of
the β-catenin gene were slightly among the adenocarcinomas
that were induced by the diﬀerent treatment regimens:
AOM/DSS, codon 32–34, 37, and 41; DMH/DSS, codon 32,
34, 37, and 41; and PhIP/DSS, codon 32 and 34 (Figure 15).
However,thesemutationswererestrictedinthecodonregion
(32–34, 37, 41, and 45) that played an important role in
degradation of β-catenin protein.
There was a report of a diﬀerence in sensitivity of
DSS-induced colitis among the species of mice [25].
To investigate whether the species diﬀerences inﬂuence
inﬂammation-associated colorectal carcinogenesis, the sen-
sitivity for diﬀerent species of mice (Balb/c, C57BL/6N,
C3H/HeN, and DBA/2N) were subjected to AOM/DSS-
induced colorectal carcinogenesis [26]. The sensitivity to8 International Journal of Inﬂammation
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Figure 10: Experimental protocol of time-course observation of AOM/DSS-induce inﬂammation-associated colorectal carcinogenesis and
tumor development (incidence and multiplicity) during the study [11].
Table 2: Animal models of colorectal carcinogenesis and inﬂammatory bowel disease. HCAs: heterocyclic amines.
(1) Animal models of colorectal carcinogenesis
(i) Carcinogen-induced animal models
Azoxymethane (AOM)
1,2-Dimethyl-hydrazine (DMH)
HCAs: 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)
2-Amino-3,8-dimethylimidazo[4,5-f] quinoxaline (MeIQx)
(ii) Mutant, transgenic, knockout animal models
Min mouse and APCΔ474 knockout mouse
(2) Animal models of inﬂammatory bowel disease
(i) Chemically and polymer-induced models
Trinitrobenzene sulfonic acid (TNBS): rat, mouse, rabbit
Dextran sulfate sodium (DSS): rat, mouse, hamster
Carrageenan: mouse, guinea pig, rabbit
(ii) Microbial-induced models
Cotton-top tamarins (Saguinus oedipus)
(iii) Mutant mice
IL-2−/−,I L - 1 0 −/−,T C R - α−/−,T C R - β−/−International Journal of Inﬂammation 9
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Figure 11: Scores of nitrotyrosine-positivity and inﬂammation in the inﬂamed colon and colonic tubular adenocarcinoma.
the AOM/DSS-induced colorectal carcinogenesis was as
follows: Balb/c > C57BL/6N   C3H/HeN = DBA/2N (Fig-
ure 16). The sensitivity was in relation to the nitrotyrosine-
positive score estimated by immunohistochemical analysis,
suggestingtheimportanceofnitrotyrosineintheAOM/DSS-
induced colorectal carcinogenesis [26].
In ApcMin/+ mice,known asananimalmodelforfamilial
adenomatous polyposis (FAP), multiple tumors (tubular
adenomas) develop in the small intestine, instead of the large
intestine in human FAP, and markedly few tumors develop
in the large bowel. However, dysplastic crypts are observed
in the colonic mucosa of ApcMin/+ mice (Figure 17)[ 27, 28].
Therefore, DSS possibly enhances the growth of dysplastic
crypts, and ﬁnally the lesions progress to adenocarcinomas.
To investigate whether DSS-induced inﬂammation in the
colonic mucosa would accelerate the growth of dysplastic
crypts, ApcMin/+ mice were given drinking water containing
2% DSS for one week without the initiation (carcinogen)
treatment [29]. Surprisingly, multiple colorectal tumors,
which were histopathologically tubular adenomas and ade-
nocarcinomas, developed four weeks after the end of DSS
treatment (Figure 18). Immunohistochemistry showed that
the developed colorectal adenocarcinomas were positive
against β-catenin, COX-2, iNOS, and p53 antibodies (Fig-
ure 19), suggesting that these factors were involved in the
development of colorectal neoplasms in the ApcMin/+ mice
by the DSS treatment, in addition to oxidative stress and
nitrosative stress. The ﬁndings suggested that DSS-induced
inﬂammation in the large bowel of ApcMin/+ mice exerts
powerfultumor-promotionand/orprogressioneﬀectsonthe
growth of dysplastic crypts, which had already existed after
the birth [27, 28].
Taken together, development of a mouse inﬂammation-
associated colorectal carcinogenesis model was brieﬂy
described here, and the model was named as the TANAKA
model. This model was possible to induce colorectal tumors
in a short-term period in rats as well by similar treatment
regimens (AOM/DSS and DMH/DSS) [30, 31]. It is antici-
pated that use of the TANAKA model will help advance the
research on elucidation of the mechanisms of inﬂammation-
associated colorectal carcinogenesis, inhibition of such car-
cinogenesis, and clariﬁcation of the mechanisms of the
tumor-promotion ability of DSS. In particular, development
of challenging research using Kyoto Apc Delta (KAD) rats in
Kyoto University will give new insight in the pathogenesis of
colorectal cancer development in the inﬂamed coon [32].10 International Journal of Inﬂammation
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Figure 13: DSS is a powerful promoter in colon carcinogenesis in mice initiated with various colonic carcinogens, azoxymethane (AOM),
1,2-dimethylhydrazine (DMH), and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) [12, 21–24, 26].International Journal of Inﬂammation 11
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Figure 14: Immunohistochemistry of PCNA, β-catenin, COX-2, and iNOS in colonic adenocarcinomas of mice induced by AOM and DSS.
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4. Exploration of Chemopreventive Agents
UsinganInﬂammation-AssociatedColorectal
CarcinogenicModel andElucidationof
theMechanisms
Studies on chemoprevention of inﬂammation-associated
colorectal carcinogenesis by several natural and synthetic
compoundsagainsthavebeenreportedusingtheAOM/DSS-
induced mouse and rat colorectal carcinogenesis mod-
els. Several are promising compounds and their clinical
application is expected. Representative compounds are
auraptene and nobiletin from citrus fruits [33], collinin
[33], β-cyclodextrin inclusion compounds of auraptene
and 4 -geranyloxyferulic acid [34], tricin [35], melatonin
[30], ursodeoxycholic acid [36], COX-2 selective inhibitor
nimesulide [37], iNOS selective inhibitors [38], PPAR lig-
ands (troglitazone and bezaﬁbrate) [37], and a lipophilic
statin pitavastatin [39]. All these compounds have anti-
inﬂammatoryactivityandareabletosuppresstheexpression
of COX-2, iNOS, and inﬂammatory cytokines.
5. Conclusions
Animal colorectal carcinogenesis models of our own making
with the background of colitis mimicking human UC
are introduced, and the exploration of chemopreventive
compounds using these animal models is described. In
addition, we conﬁrmed upregulation of Wif1, Plat, Myc, and
Plscr2 and downregulation of Pparbp, Tgfb3, and PPARγ
by comprehensive gene expression analysis in the colonic12 International Journal of Inﬂammation
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Figure 16: Macroscopic view of large bowel of four strains (Balb/c, C57BL/6N, C3H/HeN, and DBA/2N) of mice that received AOM and
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Figure 18: Macroscopic view and histopathology of colonic tumors and dysplastic crypts in APCMin/+ mice that received 2% DSS for one
week. Graphs show developments of these lesions during the study (up to 5 weeks).
mucosa of mice that received AOM and DSS [40]. Moreover,
proteomics analysis demonstrated that beta-tropomyosin,
tropomyosin 1 alpha isoform b, and S100 calcium binding
protein A9 were upregulated, while Car1, selenium-binding
protein 1, HMG-CoA synthase, thioredoxin 1, 1 Cys per-
oxiredoxin protein 2, Fcgbp protein, Cytochrome c oxidase
subunit Va, and ETHE1 protein were downregulated [41].
Signiﬁcance of expression of these genes and proteins in
inﬂammation-associated colorectal carcinogenesis remains
poorly understood and further detailed analysis is required.
Since our recent study demonstrated that NF-κBa n dN r f 2
were expressed in not only inﬂammatory cells but also
cancer cells in the TANAKA (AOM/DSS) model [34], these
molecules may be the targets for cancer chemoprevention
against colorectal cancer in the inﬂamed colon. Moreover,
modiﬁcation of the protocol of the TANAKA model may
helpustodetectenvironmentalcarcinogens[42]andtumor -
promoters [43] for the large bowel. Fortunately, the animal
models introduced here have attracted attention of young
researchers that are doing research on colorectal carcinogen-
esis, IBD, inﬂammation, and cancer. It is anticipated that use
of these models will advance elucidation of the mechanisms
(methylation and microRNA) of inﬂammation-associated
colorectal carcinogenesis, exploration of its suppression and
mechanisms, and clariﬁcation of the mechanisms of tumor-
promotion activity of DSS.14 International Journal of Inﬂammation
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Figure 19: Immunohistochemistry of β-catenin, COX-2, iNOS, and p53 in the colonic adenocarcinoma and dysplastic crypts developed
in male ApcMin/+ mice that received 2% DSS (upper panel). Apc allelic loss and gene mutations of β-catenin and K-ras in the colonic
adenocarcinoma from male ApcMin/+ mice (lower panel).
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